Kezar Life Sciences, Inc.
KZR
$4.50
$0.102.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -1.31% | -0.34% | |||
| Gross Profit | 1.31% | 0.34% | |||
| SG&A Expenses | -2.82% | 1.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.70% | 0.21% | |||
| Operating Income | 1.70% | -0.21% | |||
| Income Before Tax | 0.47% | 5.73% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.47% | 5.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.47% | 5.73% | |||
| EBIT | 1.70% | -0.21% | |||
| EBITDA | 1.72% | -0.22% | |||
| EPS Basic | -98.96% | 5.88% | |||
| Normalized Basic EPS | -99.08% | -1.07% | |||
| EPS Diluted | -98.96% | 5.88% | |||
| Normalized Diluted EPS | -99.08% | -1.07% | |||
| Average Basic Shares Outstanding | 0.05% | 0.16% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||